Claims for Patent: 11,413,360

Summary for Patent: 11,413,360

Title:	Dual mode radiotracer and—therapeutics
Abstract:	The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.
Inventor(s):	Alexander Josef Wurzer, Hans-Jürgen Wester, Matthias Johannes Eiber
Assignee:	Technische Universitaet Muenchen Klinikum Rechts Der Isar , Technische Universitaet Muenchen , Klinikum Rechts der Isar der Technischen Universitaet Muenchen
Application Number:	US16/634,759
Patent Claims:	1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt and or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18F. 2. A pharmaceutical or diagnostic composition comprising or consisting of one or more compounds according to claim 1, or a pharmaceutically acceptable salt or individual isomer thereof. 3. A method of imaging and/or diagnosing cancer comprising administering a compound according to claim 1, or a pharmaceutically acceptable salt or individual isomer thereof, to a patient in need thereof; and imaging the patient in need thereof. 4. A method of treating cancer in a patient, comprising administering an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or individual isomer thereof, to a patient. 5. A method of reducing neoangiogenesis or angiogenesis in a patient in need thereof, comprising administering an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or individual isomer thereof, to a patient in need thereof. 6. The method according to claim 4, wherein the cancer is prostate, breast, lung, colorectal or renal cell carcinoma. 7. A method of imaging and/or diagnosing neoangiogenesis or angiogenesis in a patient, comprising administering a compound according to claim 1, or a pharmaceutically acceptable salt or individual isomer thereof, to a patient in need thereof; and imaging the patient in need thereof. 8. The compound of claim 1, wherein the compound is or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18F. 9. The compound of claim 1, wherein the compound is or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18F. 10. The compound of claim 1, wherein the compound is or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18F. 11. The compound of claim 1, wherein the compound is or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18F. 12. The compound of claim 1, wherein the compound is or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18F. 13. The compound of claim 1, wherein the compound is or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18F. 14. The compound of claim 1, wherein the compound is or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18F. 15. The compound according to claim 1, or a pharmaceutically acceptable salt or individual isomer thereof, wherein the chelated cation is selected from the cations of 43Sc, 44SC, 47Sc, 64Cu, 67Cu, 67Ga, 68Ga, 90Y, 111In, 149Tb, 152Tb, 155Tb, 161Tb, 166Ho, 177Lu, 186Re, 188Re, 212Pb, 212Bi, 213Bi, 225Ac, and 227Th or a cationic molecule comprising 18F. 16. The compound according to claim 1, or a pharmaceutically acceptable salt or individual isomer thereof, wherein the fluorine atom is 18F.